Department of Vascular Surgery, Changhai Hospital, Navy (Second) Military Medical University, Shanghai, China.
Department of Vascular Surgery, the Second Hospital of Shandong University, Ji'nan, Shandong Province, China.
J Endovasc Ther. 2020 Feb;27(1):132-142. doi: 10.1177/1526602819890107. Epub 2019 Dec 2.
To evaluate the midterm outcomes of thoracic endovascular aortic repair (TEVAR) using chimney grafts (ch-TEVAR) or thoracic stent-grafts with fenestrations made on the back table (f-TEVAR) to treat thoracic aortic dissection (TAD) and thoracic aortic aneurysm (TAA). A retrospective analysis was conducted of 474 consecutive patients (mean age 62.3±10.7 years; 346 men) treated with either f-TEVAR (n=110) or ch-TEVAR (n=364) for 352 TADs (81 f-TEVAR and 271 ch-TEVAR) or 122 TAAs (29 f-TEVAR and 93 ch-TEVAR) from 2008 to 2016. The primary endpoints at 30 days and during follow-up were overall mortality, aorta-related mortality, and major complications. The secondary endpoints were endoleak and reintervention. The patency of the target branches, cost of hospitalization, and the use of antiplatelet drugs were also analyzed. Intraoperative type I endoleaks were treated in 69 (14.6%) cases (4 f-TEVAR and 65 ch-TEVAR, p<0.01) to achieve 100% technical success. Four (0.8%) patients died within 30 days [1 (0.9%) f-TEVAR and 3 (0.8%) ch-TEVAR]. Perioperative cerebral ischemia (1 fatal stroke) occurred in 9 (1.9%) patients: (1 f-TEVAR and 8 ch-TEVAR, p=0.39). During the mean follow-up of 50.6±20.0 months (49.5±18.3 months in f-TEVAR and 50.9±20.6 months in ch-TEVAR), 11 (2.3%) patients died of an aorta-related event. Type I endoleak was present in 40 (8.4%) patients (1 f-TEVAR and 39 ch-TEVAR, p<0.01). Eleven (2.3%) patients experienced stent-graft migration and 13 (2.7%) had a retrograde dissection. One hundred (16.9%) of the 593 branch stents occluded (4/75 in the f-TEVAR group and 96/518 in the ch-TEVAR group, p<0.01). The branch reintervention rate was 7.2% (34/474). The f-TEVAR group had a significantly higher probability of freedom from branch occlusion (92%) than the ch-TEVAR group (83%, p=0.007). Off-the-shelf techniques employing chimney grafts and homemade fenestrations are both suitable options for TAD and TAA involving the supra-aortic branches, with a low incidence of reintervention. Fenestrated TEVAR seems to have more favorable short- and midterm outcomes. Further study of these off-the-shelf techniques for aortic arch repair is warranted.
评估胸主动脉腔内修复术(TEVAR)中使用烟囱移植物(ch-TEVAR)或在后台制作开窗的胸主动脉支架移植物(f-TEVAR)治疗胸主动脉夹层(TAD)和胸主动脉瘤(TAA)的中期结果。对 2008 年至 2016 年间,474 例连续接受 f-TEVAR(n=110)或 ch-TEVAR(n=364)治疗的 352 例 TAD(81 例 f-TEVAR 和 271 例 ch-TEVAR)或 122 例 TAA(29 例 f-TEVAR 和 93 例 ch-TEVAR)的患者进行回顾性分析。30 天和随访期间的主要终点是总体死亡率、与主动脉相关的死亡率和主要并发症。次要终点是内漏和再介入。还分析了靶分支的通畅性、住院费用和抗血小板药物的使用。术中 I 型内漏在 69 例(14.6%)患者中得到治疗(4 例 f-TEVAR 和 65 例 ch-TEVAR,p<0.01),达到 100%的技术成功率。4 例(0.8%)患者在 30 天内死亡[1 例(0.9%)f-TEVAR 和 3 例(0.8%)ch-TEVAR]。围手术期脑缺血(1 例致命性中风)发生在 9 例(1.9%)患者中:(1 例 f-TEVAR 和 8 例 ch-TEVAR,p=0.39)。在平均 50.6±20.0 个月(f-TEVAR 为 49.5±18.3 个月,ch-TEVAR 为 50.9±20.6 个月)的随访中,11 例(2.3%)患者因主动脉相关事件死亡。40 例(8.4%)患者存在 I 型内漏(1 例 f-TEVAR 和 39 例 ch-TEVAR,p<0.01)。11 例(2.3%)患者发生支架移植物迁移,13 例(2.7%)患者发生逆行夹层。593 个分支支架中有 100 个(16.9%)闭塞(f-TEVAR 组 4/75,ch-TEVAR 组 96/518,p<0.01)。分支再介入率为 7.2%(34/474)。f-TEVAR 组的分支闭塞无复发生存率(92%)显著高于 ch-TEVAR 组(83%,p=0.007)。使用烟囱移植物和自制开窗的现货技术都是治疗涉及主动脉弓分支的 TAD 和 TAA 的合适选择,再介入率较低。开窗 TEVAR 似乎具有更有利的短期和中期结果。有必要进一步研究这些用于主动脉弓修复的现货技术。